Form 4: MPM BioVentures 2018, L.P. Reduces Stake in iTeos Therapeutics, Inc. (ITOS)

MPM BioVentures 2018, L.P., a former 10% owner of iTeos Therapeutics, Inc., reports the sale of 630,191 shares of common stock at a weighted average price of $8.06.

Summary

• MPM BioVentures 2018, L.P. filed a Form 4 indicating a change in beneficial ownership of iTeos Therapeutics, Inc. (ITOS) shares on May 13, 2025.
• The filing reports the sale of 630,191 shares of common stock.
• The shares were sold at prices ranging from $7.73 to $8.34, with a weighted average price of $8.06.
• The transaction was executed by several entities affiliated with MPM BioVentures, including MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P., and MPM Asset Management Investors BV2018 LLC.
• Following the reported transaction, MPM BioVentures 2018, L.P. and its affiliates continue to beneficially own 2,108,594 shares indirectly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a standard transaction of a venture capital firm reducing its stake. It's not inherently positive or negative, but the market's reaction will determine the short-term impact.

Negatives

• MPM BioVentures 2018, L.P. reduced its stake in iTeos Therapeutics, Inc., which could be interpreted negatively by the market.

Risks

• Continued selling pressure from MPM BioVentures 2018, L.P. could negatively impact the stock price of iTeos Therapeutics, Inc.

Industry Context

Venture capital firms often distribute shares of publicly listed companies to their limited partners or sell shares to realize gains on their investments. This transaction reflects a partial exit by MPM BioVentures from its investment in iTeos Therapeutics.

Comparison to Industry Standards

• Form 4 filings are standard practice for insiders and major shareholders when they trade shares of a publicly listed company.
• The reported transaction is similar to other instances where venture capital firms reduce their holdings in portfolio companies after an IPO or significant stock appreciation.
• Comparable companies in the biotechnology sector often see similar insider transactions as venture capital and private equity investors manage their portfolios.

Stakeholder Impact

• Shareholders may react to the news of MPM BioVentures reducing its stake, potentially leading to short-term price volatility.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as this is a financial transaction by a major shareholder.

Key Dates

Keywords

iTeos Therapeutics, ITOS, MPM BioVentures, Form 4, Beneficial Ownership, Stock Sale